First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

Share this content:
First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC
First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC), according to a study published in The Lancet Oncology.1

Because the impact of adding a third agent to platinum-doublet chemotherapy in the first-line treatment setting of patients with advanced NSCLC remains unclear, researchers sought to assess the activity and tolerability of pembrolizumab, carboplatin, and pemetrexed in this patient population.

For the phase 2 cohort of the open-label, multicohort KEYNOTE-021 study ( Identifier: NCT02039674), investigators enrolled 123 chemotherapy-naïve patients with stage IIIB or IV, nonsquamous NSCLC without targetable EGFR or ALK mutations. Participants were randomly assigned to receive 4 cycles of pembrolizumab plus platinum-doublet chemotherapy followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or 4 cycles of chemotherapy followed by pemetrexed maintenance.

Results showed that 55% (95% CI, 42-68) of the 60 patients treated with chemoimmunotherapy achieved an objective response compared with 29% (95% CI, 18-41) of patients treated with chemotherapy alone (P =.0016).

Researchers found that the incidence of grade 3 or worse treatment-related adverse events was similar between the 2 treatment arms, with the most common grade 3 or worse treatment-related adverse events in the pembrolizumab group being anemia and decreased neutrophil count.

In the chemotherapy only arm, the most frequently reported grade 3 or worse adverse events were anemia, decreased neutrophil count, pancytopenia, and thrombocytopenia.

Of note, 1 patient treated with pembrolizumab and chemotherapy experienced a treatment-related death due to sepsis vs 2 deaths in the chemotherapy arm due to sepsis and pancytopenia.

The findings ultimately suggest that the chemoimmunotherapeutic combination could be an effective and tolerable first-line treatment strategy for patients with advanced nonsquamous NSCLC. Researchers are further exploring the efficacy of this regimen in an ongoing, international, double-blind, phase 3 trial.


1. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Oct 10. doi: 10.1016/S1470-2045(16)30498-3. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs